Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen

 
• By Jo Shorthouse

Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.

Dollar bills
Janssen shows argenx the money in AML deal • Source: Shutterstock

More from Anticancer

More from Therapy Areas